The U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, major morbidity of systemic lupus erythematosus (SLE). Gazyva is a treatment for chronic lymphocytic leukemia. A monoclonal antibody, it blocks...